China-Biotics records record revenue
This article was originally published in The Tan Sheet
Executive Summary
Net sales climbed 50.1 percent to $81.4 million in the probiotics firm's fiscal 2010 ended March 31, attributed largely to increased sales of bulk additive products. With China-Biotics' new production facility online since February and China's yogurt market strongly interested in probiotics, bulk additives grew from 8.3 percent of annual revenue in 2009 to 26.8 percent in 2010, the company said June 11. Net sales in the fourth quarter were $25.5 million, up 64.3 percent. While operating income jumped to $10.8 million from $5.7 million in the January-March period, quarterly net income dipped 56.2 percent to $2.9 million and fell 21.6 percent to $15.6 million for the full year, due in part to non-cash losses from the change in value of convertible bonds. Separately, Shanghai-based China-Biotics noted it produces all 21 probiotic strains on a list of approved strains China's Ministry of Health published in May
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
P&G Restores Volume Growth In Beauty, Grooming After Pricing Run
Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.